Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for β Cell Replacement and Diabetes Disease Modeling?

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2018 Oct 22

PMID 30343423

Citations 5

Authors

Elena F Jacobson

Emmanuel S Tzanakakis

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Ever since the reprogramming of human fibroblasts to induced pluripotent stem cells (hiPSCs), scientists have been trying to determine if hiPSCs can give rise to progeny akin to native terminally differentiated cells as human embryonic stem cells (hESCs) do. Many different somatic cell types have been successfully reprogrammed via a variety of methods. In this review, we will discuss recent studies comparing hiPSCs and hESCs and their ability to differentiate to desired cell types as well as explore diabetes disease models.

Recent Findings: Both somatic cell origin and the reprogramming method are important to the epigenetic state of the hiPSCs; however, genetic background contributes the most to differences seen between hiPSCs and hESCs. Based on our review of the relevant literature, hiPSCs display differences compared to hESCs, including a higher propensity for specification toward particular cell types based on memory retained from the somatic cell of origin. Moreover, hiPSCs provide a unique opportunity for creating diabetes disease models.

Citing Articles

Dual Mode of Mitochondrial ROS Action during Reprogramming to Pluripotency.

Skvortsova E, Nazarov I, Tomilin A, Sinenko S Int J Mol Sci. 2022; 23(18).

PMID: 36142834 PMC: 9506067. DOI: 10.3390/ijms231810924.

Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?.

McKnight C, Low Y, Elliott D, Thorburn D, Frazier A Int J Mol Sci. 2021; 22(14).

PMID: 34299348 PMC: 8306397. DOI: 10.3390/ijms22147730.

Modeling Maturity Onset Diabetes of the Young in Pluripotent Stem Cells: Challenges and Achievements.

Braverman-Gross C, Benvenisty N Front Endocrinol (Lausanne). 2021; 12:622940.

PMID: 33692757 PMC: 7937923. DOI: 10.3389/fendo.2021.622940.

Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges.

Golchin A, Chatziparasidou A, Ranjbarvan P, Niknam Z, Ardeshirylajimi A Adv Exp Med Biol. 2020; 1312:19-37.

PMID: 33159303 DOI: 10.1007/5584_2020_592.

Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges.

Kamal M, Kassem D Front Cell Dev Biol. 2020; 8:16.

PMID: 32064260 PMC: 7000356. DOI: 10.3389/fcell.2020.00016.

References

Jin S, Kim K . Is islet transplantation a realistic approach to curing diabetes?. Korean J Intern Med. 2017; 32(1):62-66. PMC: 5214734. DOI: 10.3904/kjim.2016.224. View

Thurner M, Shenhav L, Wesolowska-Andersen A, Bennett A, Barrett A, Gloyn A . Genes Associated with Pancreas Development and Function Maintain Open Chromatin in iPSCs Generated from Human Pancreatic Beta Cells. Stem Cell Reports. 2017; 9(5):1395-1405. PMC: 5831005. DOI: 10.1016/j.stemcr.2017.09.020. View

Siller R, Naumovska E, Mathapati S, Lycke M, Greenhough S, Sullivan G . Development of a rapid screen for the endodermal differentiation potential of human pluripotent stem cell lines. Sci Rep. 2016; 6:37178. PMC: 5118706. DOI: 10.1038/srep37178. View

Teo A, Windmueller R, Johansson B, Dirice E, Njolstad P, Tjora E . Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. J Biol Chem. 2013; 288(8):5353-6. PMC: 3581399. DOI: 10.1074/jbc.C112.428979. View

La Spada A, Ntai A, Genovese S, Rondinelli M, De Blasio P, Biunno I . Generation of Human-Induced Pluripotent Stem Cells from Wolfram Syndrome Type 2 Patients Bearing the c.103 + 1G>A CISD2 Mutation for Disease Modeling. Stem Cells Dev. 2017; 27(4):287-295. DOI: 10.1089/scd.2017.0158. View

Hussein S, Batada N, Vuoristo S, Ching R, Autio R, Narva E . Copy number variation and selection during reprogramming to pluripotency. Nature. 2011; 471(7336):58-62. DOI: 10.1038/nature09871. View

Hosokawa Y, Toyoda T, Fukui K, Baden M, Funato M, Kondo Y . Insulin-producing cells derived from 'induced pluripotent stem cells' of patients with fulminant type 1 diabetes: Vulnerability to cytokine insults and increased expression of apoptosis-related genes. J Diabetes Investig. 2017; . PMC: 5934265. DOI: 10.1111/jdi.12727. View

Thomson J, Itskovitz-Eldor J, Shapiro S, Waknitz M, Swiergiel J, Marshall V . Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391):1145-7. DOI: 10.1126/science.282.5391.1145. View

Rezania A, Bruin J, Arora P, Rubin A, Batushansky I, Asadi A . Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014; 32(11):1121-33. DOI: 10.1038/nbt.3033. View

10.

Nishizawa M, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A . Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Cell Stem Cell. 2016; 19(3):341-54. DOI: 10.1016/j.stem.2016.06.019. View

11.

Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, Goland R . Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A. 2009; 106(37):15768-73. PMC: 2735559. DOI: 10.1073/pnas.0906894106. View

12.

Drawnel F, Boccardo S, Prummer M, Delobel F, Graff A, Weber M . Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 2014; 9(3):810-21. DOI: 10.1016/j.celrep.2014.09.055. View

13.

Pagliuca F, Millman J, Gurtler M, Segel M, Van Dervort A, Ryu J . Generation of functional human pancreatic β cells in vitro. Cell. 2014; 159(2):428-39. PMC: 4617632. DOI: 10.1016/j.cell.2014.09.040. View

14.

Teo A, Lau H, Valdez I, Dirice E, Tjora E, Raeder H . Early Developmental Perturbations in a Human Stem Cell Model of MODY5/HNF1B Pancreatic Hypoplasia. Stem Cell Reports. 2016; 6(3):357-67. PMC: 4788763. DOI: 10.1016/j.stemcr.2016.01.007. View

15.

Braverman-Gross C, Nudel N, Ronen D, Beer N, McCarthy M, Benvenisty N . Derivation and molecular characterization of pancreatic differentiated MODY1-iPSCs. Stem Cell Res. 2018; 31:16-26. DOI: 10.1016/j.scr.2018.06.013. View

16.

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

17.

Shang L, Hua H, Foo K, Martinez H, Watanabe K, Zimmer M . β-cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome. Diabetes. 2013; 63(3):923-33. PMC: 3931392. DOI: 10.2337/db13-0717. View

18.

Kim K, Zhao R, Doi A, Ng K, Unternaehrer J, Cahan P . Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol. 2011; 29(12):1117-9. PMC: 3357310. DOI: 10.1038/nbt.2052. View

19.

Rouhani F, Kumasaka N, de Brito M, Bradley A, Vallier L, Gaffney D . Genetic background drives transcriptional variation in human induced pluripotent stem cells. PLoS Genet. 2014; 10(6):e1004432. PMC: 4046971. DOI: 10.1371/journal.pgen.1004432. View

20.

Bar-Nur O, Russ H, Efrat S, Benvenisty N . Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011; 9(1):17-23. DOI: 10.1016/j.stem.2011.06.007. View